NCT07138833View on ClinicalTrials.gov

A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

August 31, 2028

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Dimethyl Fumarate Enteric-coated Capsules

Eligible 50 RMS patients will orally take dimethyl fumarate enteric-coated capsules during treatment, with an initial dose of 120 mg twice daily for 7 days, followed by a maintenance dose of 240 mg twice daily for 48 weeks

All Listed Sponsors
lead

Qilu Pharmaceutical (Hainan) Co., Ltd.

INDUSTRY